Hims & Hers Launches Peptides+ for Men
Hims & Hers has launched Peptides+, a new program focused on peptide-based treatments for men, expanding on the company’s previously announced plans to enter the peptide market following recent federal policy changes affecting peptide compounding.
According to the company, the program is designed to support areas such as recovery, performance and healthy aging through clinician-guided access to peptide therapies and related treatments. The launch follows Hims & Hers’ broader peptide initiative announced earlier this year, when the company said it intended to offer compounds including NAD+, sermorelin and glutathione, while exploring future access to peptides such as BPC-157 and TB-500 if permitted under federal policy.
The rollout comes amid continued regulatory and industry attention surrounding peptides. Last month, federal officials advanced an interim policy that could expand access to certain compounded peptides while longer-term rulemaking proceeds. As AmSpa previously reported, the policy relies on enforcement discretion and does not constitute FDA approval of the affected peptides.
Many peptide products continue to occupy a complicated regulatory position. While some are available through compounding pathways, numerous peptides promoted for recovery, longevity and wellness purposes do not have FDA-approved indications for those uses. Earlier this year, AmSpa covered the FDA’s reevaluation of several peptides, including BPC-157, KPV and Semax.
The launch underscores the growing commercial interest in peptide therapies as companies seek to expand offerings around wellness, longevity and performance optimization. It also highlights the ongoing evolution of the peptide market as regulators continue to evaluate the safety, efficacy and appropriate regulatory framework for these products.
